CD274 and non-small cell lung carcinoma: Of the 18 NTRK fusion-positive patients with NSCLC, 6 had PD-L1 IHC expression with TPS ≥1–49%, and 6 had TPS ≥50% for consideration of pembrolizumab (Figure 1B; Supplementary Table S2).